These findings suggest that JTTZF is a therapeutic agent in inhibiting STING‐restored metabolic homeostasis for the management of obesity‐related T2D via the cGAS‐STING/TBK1/NF‐κB pathway. Here, NFKB1 is linked to obesity due to melanocortin 4 receptor deficiency.